There won’t be a single cancer vaccine, but rather a different one for each patient and tumor

“We’ve been living with the promise of cancer vaccines for, probably, 100 years. Until now, all we had were studies that were inconclusive, but this one is conclusive.” Immunologist Antoni Ribas of the University of California Los Angeles (UCLA), who is part of the scientific committee for the Moderna and MSD (Merck in the U.S. and Canada) melanoma vaccine trial that made headlines last week, says he learned of the announcement when a reporter called him to ask about the results. Ribas says that despite his proximity to the project, he was not shown concrete data on the vaccine’s benefit. “With announcements of this magnitude, which can have a big impact on share prices, they do not give anyone the data in advance and they must notify everyone at the same time,” he explains.

Seguir leyendo